Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical CystectomyErik J van Gennep, Francesco Claps, Peter J Bostrom, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Cancer Discovery|April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase EpsilonBenoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
Pageof 8